New state-of-the-art cleanroom boosts production of anticancer drugs15 Jul 2019
The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.
Production of new anticancer drugs at ADC Bio’s North Wales manufacturing plant has been boosted following completion of a new cleanroom facility, designed and built by WHP. This forms a key part of ADC Bio’s construction of a new bioconjugation facility at its site in Deeside, North Wales, UK for the commercial production of antibody drug conjugates in response to global customer demand.
Antibody drug conjugates are a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards.
WHP, the multi-disciplinary engineering company, was awarded the £5m contract in December 2017, and the new facility – which includes support areas for washing, depyrogenation, thawing and buffer preparation – sees drug manufacturing in a stringently controlled environment, operated under cGMP regulations. This eliminates any risks during antibody modification and conjugation that could support the development of environmentally-borne microbial contaminants.
WHP’s scope of work covered the design and build, including test and validation of a state-of-the-art containment manufacturing cleanroom within an existing 6,500 m2 high tech facility, along with new quality control and process development laboratories.
Auto-cad design work encompassed cleanroom architecture, M&E components and process and critical utilities systems. Also featuring complex zoned HVAC systems to maintain segregation, cleanliness, air pressures, and other environmental controls, the cleanroom facilities have been developed in compliance with MHRA regulations.
A key feature of the project has been the installation of a bespoke low maintenance toxic waste system, developed by WHP to remove cleanroom waste to a holding tank, where it is transported to an off-site incinerator. This system incorporates dry break couplers to seal off both ends of the pipeline to prevent the possibility of any onsite contamination.
Charlie Johnson, CEO at ADC Bio, added: “We are building a best-in-class facility to the highest possible global standards. We awarded the contract to WHP on the back of its relevant industry experience and reputation for delivering cost-effective, single source cleanroom design and build packages. It’s a facility we are extremely proud of that will help our customers develop vital new medicines for patients globally.”
WHP’s project manager, Chris Douglas said: “The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure and highly efficient manufacturing capabilities. This latest project reflects growing success in delivering high-quality cleanroom technologies across the pharmaceutical sector, providing customers with expertise, knowledge and one-stop-shop solutions.”
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Catalent completes purchase of biologics fill-finish and oral solid dose facility
7 Jan 2020
Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.Read more
Boxing clever: Smart packs improving communication with patients
6 Jan 2020
Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.Read more
WuXi STA opens large-scale oligonucleotide manufacturing facility
6 Jan 2020
Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.Read more
NIH researchers discover new autoinflammatory disease
3 Jan 2020
Mutations in the RIPK1 gene responsible for CRIA syndrome.Read more
UCB to build new biotech manufacturing plant in Belgium
31 Dec 2019
Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.Read more
BioAscent scientists help identify potential new treatments for cancer
30 Dec 2019
Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.Read more
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences
27 Dec 2019
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation